To the Editor This letter addresses the methods in an Original Investigation titled “Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval” by Prasad and Mailankody1 and published in a recent issue of JAMA Internal Medicine. Specifically, it calls attention to the fact that these methods do not appropriately apply accounting or finance standards, and, consequently, measure neither “spending” nor “revenues.”
Ledley FD. Methods Used to Assess Pharmaceutical Research and Development Costs. JAMA Intern Med. 2018;178(4):589. doi:10.1001/jamainternmed.2018.0110
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.